SCHEMBL30765983

SCHEMBL30765983

CCCCOC(=O)Cn1c(C2CCCC2)ncc(NCc2ccc3oc4ccccc4c3c2)c1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.38
GAA P10253 2/20 0.38
ELANE P08246 1/20 0.38
TP53 P04637 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
HCRTR1 O43613 4/20 0.37
HCRTR2 O43614 4/20 0.37
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
LMNA P02545 4/20 0.35
MAPT P10636 4/20 0.35
ALDH1A1 P00352 3/20 0.35
KDM4E B2RXH2 2/20 0.35
HPGD P15428 2/20 0.35
TDP1 Q9NUW8 1/20 0.35
RAB9A P51151 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
POLB P06746 1/20 0.35
HTT P42858 1/20 0.35
AGTR1 P30556 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765777 0.87 HCRTR1 (0.40) L3MBTL1GAAELANETP53SMN1; SMN2
SCHEMBL30765580 0.86 ELANE (0.39) L3MBTL1ELANESMN1; SMN2HCRTR1HCRTR2
SCHEMBL30765926 0.85 GAA (0.52) L3MBTL1GAAELANETP53SMN1; SMN2
SCHEMBL30765891 0.85 GAA (0.40) L3MBTL1GAATP53SMN1; SMN2MEN1
SCHEMBL30765884 0.83 GAA (0.40) L3MBTL1GAATP53SMN1; SMN2HCRTR1
SCHEMBL30766100 0.81 GAA (0.42) L3MBTL1GAATP53SMN1; SMN2MEN1
SCHEMBL30765601 0.81 GAA (0.44) L3MBTL1GAAELANETP53SMN1; SMN2
SCHEMBL30765921 0.78 GAA (0.42) L3MBTL1GAAELANETP53SMN1; SMN2
SCHEMBL30765643 0.77 NAMPT (0.35) ELANELMNAALDH1A1
SCHEMBL30766108 0.77 GAA (0.39) L3MBTL1GAATP53SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed